Heart Transplant Failure
9
4
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
Levothyroxine Supplementation for Heart Transplant Recipients
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
Impact of Atelectasis on RVEDP Following Orthotropic Heart Transplantation
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Safety and Effectiveness of NRP for DCD Heart Transplantation
Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation
Levels of High-Sensitivity C-Reactive Protein in Heart Transplant Patients